← Eichor
Study identifier: NCT06213168 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Impact on Mortality of a Strategy Including Continuous Positive Airway Pressure Plus High Flow Nasal Cannula Oxygen Therapy Versus High Flow Nasal Cannula Oxygen Therapy Alone in Patients With de Novo Acute Hypoxemic Respiratory Failure: a Prospective, Randomized Controlled Trial.

Condition: De Novo Hypoxemic Acute Respiratory Failure (hARF)  ·  Sponsor: Assistance Publique - Hôpitaux de Paris

PhaseNA
Planned participants1084
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

De novo hypoxemic acute respiratory failure (hARF) is one of the main causes of intensive care unit (ICU) admission. In de novo hARF, intubation is associated with a dramatic increase in mortality rate. Compared to standard oxygen, the use of high-flow oxygen nasal cannula (HFNC) might be beneficial to prevent intubation and mortality, although the results of trials and meta-analyses are conflicting. Even with HFNC, the intubation rate remains high. This is the reason why adjunctive therapies, administered in addition to HFNC are needed. Continuous positive airway pressure (CPAP) is one of these adjunctive therapies. CPAP provides high level of positive end-expiratory pressure that ensures lung recruitment, but without adding inspiratory pressure support, which prevents ventilator induced lung injury. In addition, as opposed to pressure support, CPAP is well tolerated during long periods of time. Therefore, applying CPAP in addition to HFNC may reduce intubation rate and in turn mortality rate. The present trial will evaluate the impact on mortality of a strategy including continuous positive airway pressure plus high flow nasal cannula oxygen therapy versus high flow nasal cannula oxygen therapy alone in patients with de novo acute hypoxemic respiratory failure: a Prospective, Randomized Controlled Trial

This description comes directly from the study's public registry record.

Talk to the study team

Alexandre DEMOULE  ·  +33 (0)1 42 16 77 61  ·  alexandre.demoule@aphp.fr

Always discuss trial participation with your own doctor first.

Locations (29)

CHU Amiens-PicardieAmiens, FranceNot Yet Recruiting
CHU AngersAngers, FranceNot Yet Recruiting
Centre Hospitalier Victor DupouyArgenteuil, FranceNot Yet Recruiting
Hôpital AvicenneBobigny, FranceNot Yet Recruiting
Centre Hospitalier de Bourg-en-Bresse - Site de FleyriatBourg-en-Bresse, FranceRecruiting
Hôpital Louis-MourierColombes, FranceNot Yet Recruiting
Centre Hospitalier Sud FrancilienCorbeil-Essonnes, FranceNot Yet Recruiting
Hôpital Henri-MondorCréteil, FranceRecruiting
Centre Hospitalier de Dieppe - Site PasteurDieppe, FranceRecruiting
Hôpital François MitterrandDijon, FranceRecruiting
Hôpital André MignotLe Chesnay, FranceRecruiting
Hôpital BicêtreLe Kremlin-Bicêtre, FranceNot Yet Recruiting

+ 17 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06213168